Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the third quarter ended September 30, 2008.

"We continue to make rapid progress in both of our hepatitis C development programs," said Steve Worland Ph.D., President and CEO of Anadys. "We completed our first clinical study of ANA598 in healthy volunteers and have now completed the healthy volunteer portion of our ongoing ANA773 study. For both programs, we are very encouraged by the data and look forward to initiating patient dosing this quarter."

Financial Results

As of September 30, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $34.4 million.

During the third quarter of 2008 the Company had no revenue, compared to $21.5 million for the same quarter of 2007. The revenue in the third quarter of 2007 was primarily derived from the recognition of previously deferred revenue associated with an upfront payment and a milestone payment under a prior collaboration.

Research and development expenses were $7.6 million for the third quarter of 2008 and 2007. During the third quarter of 2008, cost savings derived from Anadys' completed strategic restructuring and associated termination of prior development programs were offset by a significant increase in ANA598 development costs.

General and administrative expenses were $2.1 million for the third quarter of 2008, compared to $2.4 million for the third quarter of 2007. The $0.3 million decrease primarily resulted from cost savi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... , ... CSM, a leading clinical trial supply company, today announced that Michael ... extensive background in financial management and accounting, bringing over 20 years of experience in ... will oversee all financial areas of the company to both strengthen CSM’s financial strategy ...
(Date:7/6/2015)... ... July 06, 2015 , ... A study ... insights into how virulent fungi adapt through genetic modifications to fight back against ... leaves them temporarily weakened. These insights may provide clues to new ways to ...
(Date:7/6/2015)... Wellesley, Mass. (PRWEB) , ... July 06, 2015 ... ... development of simpler and cheaper molecular diagnostic tests are key drivers of the ... projected growth of personalized medicine and the introduction of new companion diagnostic tests ...
(Date:7/6/2015)... -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today ... Clinical (Novella), to conduct the phase 3 registration ... Novella is a full-service, global clinical research organization (CRO) ... companies. The ICT-107 phase 3 trial will include approximately ... and Canada , and ...
Breaking Biology Technology:CSM Appoints Michael Morse as Vice President of Finance 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 4Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 2Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2
... on a poultry farm in Texas. Soon, there are reports ... and New Jersey. How can health officials be mobilized to ... humans? , ,That process may well begin at the All-Emergency ... Services Secretary Tommy Thompson to keep tabs on the range ...
... , today announced the addition of two new members ... Weis. , ,The Madison-based media communications company hopes to ... its board of directors with the appointments. Peercy and ... meeting, at which time they will stand for election. ...
... intranets are frustrated. In a recent Moreover survey, 58 ... information resource at work, but only 11 percent considered ... Given all the money and effort that has gone ... value in them? , ,By 1998, companies were already ...
Cached Biology Technology:Federal command center is at the front line of defense for public health emergencies 2Federal command center is at the front line of defense for public health emergencies 3The unfilled promise of corporate intranets 2The unfilled promise of corporate intranets 3
(Date:6/12/2015)... 12, 2015  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announced the ... electronically capture, analyze and identify participants of a ... This system can: , ... and subsequent sign-on process is actually the person ...
(Date:6/10/2015)... 10, 2015 According to ... by Technology (Ultrasound, TOF, Structured Light, Stereo Vision), ... Automotive) and by Geography - Trends & Forecast ... market is expected to reach $3,319.71 Million by ... 2015 and 2020. Browse 71 market ...
(Date:6/9/2015)... DUBLIN , June 09, 2015 ... the addition of the "Gesture Recognition & ... Application (Consumer Electronics, Automotive, & Others), Product (Biometric ... Forecast to 2020" report to their offering. ... sensing market is expected to reach $ 23.55 ...
Breaking Biology News(10 mins):Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 23D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... of folic acid around the time of conception and throughout ... one day deserve a spot on the obstetrician,s list of ... choline a nutrient found in eggs and meat ... such as mental health disturbances, and chronic conditions, like hypertension, ...
... floating islands containing papyrus plants to help protect the ... Kenya. The German REWE Group is funding a ... grower Finlays and Dr David Harper, a Senior Lecturer ... the water-cleansing services of papyrus as artificial floating islands. ...
... Sept. 20, 2012 Novetta Solutions, LLC (Novetta), ... announced the acquisition of International Biometric Group, LLC ... to customers within the National Security community and ... Novetta was established in March 2012 through the ...
Cached Biology News:Nutrient in eggs and meat may influence gene expression from infancy to adulthood 2Nutrient in eggs and meat may influence gene expression from infancy to adulthood 3Novel plastic-and-papyrus restoration project 2Novel plastic-and-papyrus restoration project 3Novetta Solutions Acquires International Biometric Group, LLC 2Novetta Solutions Acquires International Biometric Group, LLC 3
Homo sapiens postsynaptic protein CRIPT Antigen: Recombinant Protein...
... quadrupole 1200L sets the new standard ... - incorporating the latest technologies and ... chromatography analytical needs. The Atmospheric ... Transmission Quadrupole Analyzer provide superior selectivity ...
Human Legumain Affinity Purified Polyclonal Ab...
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
Biology Products: